Why the study?
There was limited information on the safety and efficacy of triple therapy with prostanoids in patients with pulmonary arterial hypertension associated with congenital heart disease.
Does the addition of prostanoid triple therapy improve functional class, 6MWTD, and NT-proBNP levels in patients with PAH-CHD already on maximal dual combination therapy?
Does the addition of prostanoid triple therapy improve functional class, 6MWTD, and NT-proBNP levels in patients with PAH-CHD already on maximal dual combination therapy?
The addition of prostanoid triple therapy in patients with PAH-CHD on maximal dual therapy is safe and significantly improves exercise capacity, functional class, and NT-proBNP levels over 2 years.
Answers are grounded in this paper and cite their sources.
May support triple therapy escalation in PAH-CHD on dual therapy; leaves open need for RCTs before practice change.
OBJECTIVE: This study assessed the long-term effects of triple therapy with prostanoids on patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), as there is limited information on the safety and efficacy of this treatment approach. METHODS: A retrospective cohort study was conducted on patients with PAH-CHD who were actively followed up at our centre. All patients were already receiving dual combination therapy at maximum doses. Clinical characteristics, including functional class (FC), 6-minute walking test distance (6MWTD) and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, were documented before initiating triple therapy and annually for a 2-year follow-up period. RESULTS: A total of 60 patients were included in the study, with a median age of 41 years and 68% being women. Of these, 32 had Eisenmenger syndrome, 9 had coincidental shunts, 18 had postoperative PAH and 1 had a significant left-to-right shunt. After 1 year of triple combination initiation, a significant improvement in 6MWTD was observed (406 vs 450; p=0.0027), which was maintained at the 2-year follow-up. FC improved in 79% of patients at 1 year and remained stable in 76% at 2 years. NT-proBNP levels decreased significantly by 2 years, with an average reduction of 199 ng/L. Side effects were experienced by 33.3% of patients but were mostly mild and manageable. Subgroup analysis showed greater benefits in patients without Eisenmenger syndrome and those with pre-tricuspid defects. CONCLUSIONS: Triple therapy with prostanoids is safe and effective for patients with PAH-CHD, improving FC, 6MWTD and NT-proBNP levels over 2 years. The treatment is particularly beneficial for patients with pre-tricuspid defects and non-Eisenmenger PAH-CHD.
No takes yet. Share an insight, caveat, or question.
Luna‐López et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: